Coherus Slapped With CRL for Neulasta Biosimilar BLA Due to Third-Party Filler

The FDA issued a complete response letter (CRL) to Coherus Biosciences on its BLA for a biosimilar of Neulasta (pegfilgrastim) solely due to an ongoing review of inspection findings at a third-party filler, the company said.
Source: Drug Industry Daily